Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Colorcon
Citi
Queensland Health
Fuji
US Army

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 9,198,966

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,198,966
Title:B-type plexin antagonists and uses thereof
Abstract: The present invention concerns the field of cancer therapy. In particular, it relates to an antagonist of a B-type plexin which prevents the interaction of the B-type plexin with ErbB-2 for use as a medicament, in particular, for treating metastasizing cancer. The present invention also contemplates a method for identifying an antagonist which prevents the interaction of a B-type plexin with ErbB-2. Finally, the invention provides for a polynucleotide encoding a B-type plexin polypeptide which lacks a functional intracellular domain and the said polypeptide.
Inventor(s): Offermanns; Stefan (Bad Nauheim, DE), Swiercz; Jakub (Bad Nauheim, DE), Worzfeld; Thomas (Bad Nauheim, DE)
Assignee: Ruprecht-Karls-Universitat Heidelberg (Heidelberg, DE) Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. (Munich, DE)
Application Number:13/983,715
Patent Claims:see list of patent claims

Details for Patent 9,198,966

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial Ruprecht-Karls-Universitat Heidelberg (Heidelberg, DE) Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. (Munich, DE) 2031-02-09 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Try a Free Trial Ruprecht-Karls-Universitat Heidelberg (Heidelberg, DE) Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. (Munich, DE) 2031-02-09 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Try a Free Trial Ruprecht-Karls-Universitat Heidelberg (Heidelberg, DE) Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. (Munich, DE) 2031-02-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
US Army
Chubb
Healthtrust
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.